BC Week In Review | Jan 20, 2014
Company News

Elixir Medical sales and marketing update

Elixir launched its DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System in Europe to treat coronary artery disease (CAD). The scaffold is available in diameters of 3, 3.25 and 3.5 mm and lengths of 14, 18...
BC Week In Review | May 20, 2013
Clinical News

DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System regulatory update

Elixir received CE Mark approval for its DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System to treat coronary artery disease (CAD). Elixir plans to launch the product later this year. The system is a poly-L lactide...
Items per page:
1 - 2 of 2